文献检索，用中文搜 PubMed

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

Michalski - Hüttermann and Partner Patent Attorneys; Duesseldorf, Germany.

MAbs. 2012 Mar-Apr;4(2):274-80. doi: 10.4161/mabs.4.2.19253. Epub 2012 Mar 1.

This article discusses the status quo of the Cabilly patents, their scope of protection and the role these patents play for the therapeutic antibody industry in Europe and the US.

本文讨论了卡比利专利的现状、其保护范围以及这些专利对欧美治疗性抗体行业所起的作用。

相似文献

The Cabilly patents: status quo and relevance for antibody companies.卡比利专利：抗体公司的现状及相关性

MAbs. 2012 Mar-Apr;4(2):274-80. doi: 10.4161/mabs.4.2.19253. Epub 2012 Mar 1.

Cabilly patent finale.卡比利专利终稿。

Nat Biotechnol. 2008 Aug;26(8):846. doi: 10.1038/nbt0808-846b.

Genentech's Cabilly victory.基因泰克公司在卡比利专利案中的胜诉。

Nat Biotechnol. 2009 Apr;27(4):307. doi: 10.1038/nbt0409-307.

Four rebuffs for Cabilly.

Nat Biotechnol. 2008 Apr;26(4):362. doi: 10.1038/nbt0408-362a.

Herbal drug patenting in India: IP potential.印度草药药品专利：知识产权潜力。

J Ethnopharmacol. 2011 Sep 1;137(1):289-97. doi: 10.1016/j.jep.2011.05.022. Epub 2011 May 27.

The transatlantic divide: how divisional and continuing patent application filing practice differs between the USA and Europe.

Pharm Pat Anal. 2012 Jul;1(3):245-8. doi: 10.4155/ppa.12.36.

Intellectual property protection: strategies for antibody inventions.知识产权保护：抗体发明的策略。

MAbs. 2011 May-Jun;3(3):310-7. doi: 10.4161/mabs.3.3.15530. Epub 2011 May 1.

[Drug patents and other ways to protect pharmaceutical research].

Therapie. 2004 Mar-Apr;59(2):253-7. doi: 10.2515/therapie:2004049.

An export-only exception to pharmaceutical patents in Europe: should the United States follow suit?欧洲药品专利的仅出口例外：美国是否应效仿？

Nat Biotechnol. 2019 Jan 3;37(1):21-22. doi: 10.1038/nbt.4324.

Obtaining, challenging and enforcing pharmaceutical patents under the America Invents Act.根据《美国发明法案》获取、质疑和执行药品专利。

Pharm Pat Anal. 2012 Sep;1(4):415-26. doi: 10.4155/ppa.12.51.

引用本文的文献

Assessing concentration in the monoclonal antibody innovation market: A patent-based study.评估单克隆抗体创新市场的集中度：一项基于专利的研究。

PLoS One. 2025 Mar 27;20(3):e0320864. doi: 10.1371/journal.pone.0320864. eCollection 2025.

Gene patent practice across plant and human genomes.植物和人类基因组中的基因专利实践。

Nat Biotechnol. 2015 Oct;33(10):1033-8. doi: 10.1038/nbt.3364.

Rituximab: how approval history is reflected by a corresponding patent filing strategy.利妥昔单抗：相应的专利申请策略如何反映其获批历程。

MAbs. 2014 Jul-Aug;6(4):820-37. doi: 10.4161/mabs.29105. Epub 2014 May 19.

本文引用的文献

Intellectual property protection: strategies for antibody inventions.知识产权保护：抗体发明的策略。

MAbs. 2011 May-Jun;3(3):310-7. doi: 10.4161/mabs.3.3.15530. Epub 2011 May 1.

Engineered protein scaffolds as next-generation antibody therapeutics.工程化蛋白质支架作为下一代抗体疗法

Curr Opin Chem Biol. 2009 Jun;13(3):245-55. doi: 10.1016/j.cbpa.2009.04.627. Epub 2009 Jun 6.

Michalski - Hüttermann and Partner Patent Attorneys; Duesseldorf, Germany.

MAbs. 2012 Mar-Apr;4(2):274-80. doi: 10.4161/mabs.4.2.19253. Epub 2012 Mar 1.

This article discusses the status quo of the Cabilly patents, their scope of protection and the role these patents play for the therapeutic antibody industry in Europe and the US.

本文讨论了卡比利专利的现状、其保护范围以及这些专利对欧美治疗性抗体行业所起的作用。